Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer Read more about Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer Read more about A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL Read more about Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Read more about A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1) Read more about Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)
Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly Read more about Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly
Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer Read more about Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies Read more about A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer Read more about Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer
Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma Read more about Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma